Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises La Française des Jeux SA on its public offer for Kindred Group plc
Mandate

Vinge advises La Française des Jeux SA on its public offer for Kindred Group plc

January 22, 2024 Capital Markets and Public M&A Banking and Finance

La Française des Jeux SA, France’s national lottery and leading betting and gaming operator, has announced a recommended public offer to the shareholders of Kindred Group plc regarding the SDRs in Kindred Group plc that are admitted to trading on Nasdaq Stockholm. Through the transaction, La Française des Jeux SA strengthens its position in Europe within gambling and betting.

Across its portfolio of iconic brands, Kindred Group plc is a trusted source of safe, fair, and sustainable entertainment for 1.6 million active customers. The transaction will create a European gaming champion with increased scale, technology and content capabilities and greater diversification. The transaction is also consistent with best-in-class sustainability and responsible gaming approach.

The total value of the offer is approximately SEK 28 billion. Vinge advises La Française des Jeux SA.

The Vinge team includes David Andersson, Erik Sjöman, William Kåge, Gabriel Chabo and Isabell Bitar (Capital Markets and Public M&A) as well as Louise Brorsson Salomon and Helena Göransson (Banking and finance).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026